Measuring impact of benign thyroid diseases on quality of life
Publikation: Bidrag til bog/antologi/rapport › Bidrag til bog/antologi › Forskning › fagfællebedømt
Quality of life (QoL), defined as “the subjective assessment of the impact of disease and its treatment across the physical, psychological, social, and somatic domains of functioning and well-being,” is measured by patient-reported outcomes, abbreviated PRO. PROs may be generic or disease specific. This article focuses on the latter, by reviewing existing thyroid-specific QoL measures or “PROs.” Thirteen instruments were reviewed, characterized and had their measurement properties evaluated. Eight of these were developed in accordance with current standards: Three instruments for patients with Graves’ orbitopathy: Graves’ orbitopathy quality of life instrument (GO-QOL), Graves’ ophthalmopathy quality of life scale (GO-QLS) and Thyroid eye disease quality of life scale (TED-QOL) and one triplet of instruments for patients with hypothyroidism, Underactive thyroid-dependent quality of life questionnaire (ThyDQoL), Thyroid symptom rating questionnaire (ThySRQ) and Thyroid treatment satisfaction questionnaire (ThyTSQ) and Thyroid-related patient reported outcome (ThyPRO/ThyPRO-39 (short-form)), for patients with any benign thyroid disease, and thus the only PRO validated for use among patients with non-toxic goiter and hyperthyroidism.
|Titel||Encyclopedia of Endocrine Diseases|
|Status||Udgivet - 2018|
© 2019 Elsevier Inc.